论文部分内容阅读
罗氟司特(roflumilast,1)化学名为N-(3,5-二氯吡啶-4-基)-3-环丙甲氧基-4-二氟甲氧基苯甲酰胺,是由德国安达(Altana)公司研发,瑞士奈科明公司(Nycomed Pharma GmbH)完成Ⅲ期临床试验的磷酸二酯酶4(PDE4)抑制剂,于2010年7月在欧洲获得批准,随后在德国、英国和西班牙上市,商品名为Daxas。2011年3月又获得美国FDA批准,在美国上市。该药是十多年来首个
Roflumilast (1) has the chemical name N- (3,5-dichloropyridin-4-yl) -3-cyclopropylmethoxy-4-difluoromethoxybenzamide, The phosphodiesterase 4 (PDE4) inhibitor, developed by Altana and developed by Phase III of Nycomed Pharma GmbH in Switzerland, was approved in Europe in July 2010 and subsequently approved in Germany, the United Kingdom and the United Kingdom Spanish listing, trade name Daxas. In March 2011, it was approved by the U.S. FDA and marketed in the United States. This medicine is the first in more than a decade